Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy

Edoardo G. Giannini, Simona Marenco, Valentina Fazio, Giulia Pieri, Vincenzo Savarino, Antonino Picciotto

Research output: Contribution to journalArticle

Abstract

Background: In patients with chronic hepatitis C virus (HCV) infection, the presence of peripheral blood cytopaenia may represent an obstacle to pegylated interferon and ribavirin treatment. Aims: To evaluate the prevalence of anaemia, neutropaenia and thrombocytopaenia potentially limiting initiation of pegylated interferon and ribavirin treatment in patients with chronic HCV infection who were otherwise eligible for antiviral therapy. Methods: We studied 3059 consecutive anti-HCV and HCV-RNA positive patients referred to our centre to be evaluated for antiviral therapy from June 2002 to May 2011. The European Association for the Study of Liver HCV guidelines were applied to assess eligibility for antiviral therapy. Results: In the study cohort, 1,521 patients (49.7%) were not eligible for treatment because of reasons different from haematological abnormalities. In the remaining 1,538 patients the overall prevalence of any peripheral blood cytopaenia potentially preventing patients from being treated with antiviral therapy was 15.1%. In particular, anaemia (haemoglobin level <12 g/dL for women, 9/L) and neutropaenia (absolute neutrophil count <1.5 × 109/L) limited treatment in 6.5% (100/1358) and 3.2% (48/1358) of patients respectively. These haematological abnormalities were more prevalent in patients with older age (P <0.004) and cirrhosis (P <0.001). Conclusions: The presence of peripheral blood cytopaenia may potentially limit initiation of antiviral therapy in one in every seven patients with chronic HCV infection who are otherwise eligible for treatment.

Original languageEnglish
Pages (from-to)1113-1119
Number of pages7
JournalLiver International
Volume32
Issue number7
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Chronic Hepatitis C
Antiviral Agents
Hepacivirus
Virus Diseases
Therapeutics
Ribavirin
Interferons
Anemia
Hemoglobins
Neutrophils
Fibrosis
Cohort Studies
Guidelines
RNA
Liver

Keywords

  • Anaemia
  • Hepatitis c virus
  • Neutropaenia
  • Pegylated interferon
  • Thrombocytopaenia

ASJC Scopus subject areas

  • Hepatology

Cite this

Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. / Giannini, Edoardo G.; Marenco, Simona; Fazio, Valentina; Pieri, Giulia; Savarino, Vincenzo; Picciotto, Antonino.

In: Liver International, Vol. 32, No. 7, 08.2012, p. 1113-1119.

Research output: Contribution to journalArticle

Giannini, Edoardo G. ; Marenco, Simona ; Fazio, Valentina ; Pieri, Giulia ; Savarino, Vincenzo ; Picciotto, Antonino. / Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. In: Liver International. 2012 ; Vol. 32, No. 7. pp. 1113-1119.
@article{0ac424807ca84d03a33395256b92fca9,
title = "Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy",
abstract = "Background: In patients with chronic hepatitis C virus (HCV) infection, the presence of peripheral blood cytopaenia may represent an obstacle to pegylated interferon and ribavirin treatment. Aims: To evaluate the prevalence of anaemia, neutropaenia and thrombocytopaenia potentially limiting initiation of pegylated interferon and ribavirin treatment in patients with chronic HCV infection who were otherwise eligible for antiviral therapy. Methods: We studied 3059 consecutive anti-HCV and HCV-RNA positive patients referred to our centre to be evaluated for antiviral therapy from June 2002 to May 2011. The European Association for the Study of Liver HCV guidelines were applied to assess eligibility for antiviral therapy. Results: In the study cohort, 1,521 patients (49.7{\%}) were not eligible for treatment because of reasons different from haematological abnormalities. In the remaining 1,538 patients the overall prevalence of any peripheral blood cytopaenia potentially preventing patients from being treated with antiviral therapy was 15.1{\%}. In particular, anaemia (haemoglobin level <12 g/dL for women, 9/L) and neutropaenia (absolute neutrophil count <1.5 × 109/L) limited treatment in 6.5{\%} (100/1358) and 3.2{\%} (48/1358) of patients respectively. These haematological abnormalities were more prevalent in patients with older age (P <0.004) and cirrhosis (P <0.001). Conclusions: The presence of peripheral blood cytopaenia may potentially limit initiation of antiviral therapy in one in every seven patients with chronic HCV infection who are otherwise eligible for treatment.",
keywords = "Anaemia, Hepatitis c virus, Neutropaenia, Pegylated interferon, Thrombocytopaenia",
author = "Giannini, {Edoardo G.} and Simona Marenco and Valentina Fazio and Giulia Pieri and Vincenzo Savarino and Antonino Picciotto",
year = "2012",
month = "8",
doi = "10.1111/j.1478-3231.2012.02798.x",
language = "English",
volume = "32",
pages = "1113--1119",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy

AU - Giannini, Edoardo G.

AU - Marenco, Simona

AU - Fazio, Valentina

AU - Pieri, Giulia

AU - Savarino, Vincenzo

AU - Picciotto, Antonino

PY - 2012/8

Y1 - 2012/8

N2 - Background: In patients with chronic hepatitis C virus (HCV) infection, the presence of peripheral blood cytopaenia may represent an obstacle to pegylated interferon and ribavirin treatment. Aims: To evaluate the prevalence of anaemia, neutropaenia and thrombocytopaenia potentially limiting initiation of pegylated interferon and ribavirin treatment in patients with chronic HCV infection who were otherwise eligible for antiviral therapy. Methods: We studied 3059 consecutive anti-HCV and HCV-RNA positive patients referred to our centre to be evaluated for antiviral therapy from June 2002 to May 2011. The European Association for the Study of Liver HCV guidelines were applied to assess eligibility for antiviral therapy. Results: In the study cohort, 1,521 patients (49.7%) were not eligible for treatment because of reasons different from haematological abnormalities. In the remaining 1,538 patients the overall prevalence of any peripheral blood cytopaenia potentially preventing patients from being treated with antiviral therapy was 15.1%. In particular, anaemia (haemoglobin level <12 g/dL for women, 9/L) and neutropaenia (absolute neutrophil count <1.5 × 109/L) limited treatment in 6.5% (100/1358) and 3.2% (48/1358) of patients respectively. These haematological abnormalities were more prevalent in patients with older age (P <0.004) and cirrhosis (P <0.001). Conclusions: The presence of peripheral blood cytopaenia may potentially limit initiation of antiviral therapy in one in every seven patients with chronic HCV infection who are otherwise eligible for treatment.

AB - Background: In patients with chronic hepatitis C virus (HCV) infection, the presence of peripheral blood cytopaenia may represent an obstacle to pegylated interferon and ribavirin treatment. Aims: To evaluate the prevalence of anaemia, neutropaenia and thrombocytopaenia potentially limiting initiation of pegylated interferon and ribavirin treatment in patients with chronic HCV infection who were otherwise eligible for antiviral therapy. Methods: We studied 3059 consecutive anti-HCV and HCV-RNA positive patients referred to our centre to be evaluated for antiviral therapy from June 2002 to May 2011. The European Association for the Study of Liver HCV guidelines were applied to assess eligibility for antiviral therapy. Results: In the study cohort, 1,521 patients (49.7%) were not eligible for treatment because of reasons different from haematological abnormalities. In the remaining 1,538 patients the overall prevalence of any peripheral blood cytopaenia potentially preventing patients from being treated with antiviral therapy was 15.1%. In particular, anaemia (haemoglobin level <12 g/dL for women, 9/L) and neutropaenia (absolute neutrophil count <1.5 × 109/L) limited treatment in 6.5% (100/1358) and 3.2% (48/1358) of patients respectively. These haematological abnormalities were more prevalent in patients with older age (P <0.004) and cirrhosis (P <0.001). Conclusions: The presence of peripheral blood cytopaenia may potentially limit initiation of antiviral therapy in one in every seven patients with chronic HCV infection who are otherwise eligible for treatment.

KW - Anaemia

KW - Hepatitis c virus

KW - Neutropaenia

KW - Pegylated interferon

KW - Thrombocytopaenia

UR - http://www.scopus.com/inward/record.url?scp=84863518029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863518029&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2012.02798.x

DO - 10.1111/j.1478-3231.2012.02798.x

M3 - Article

C2 - 22471814

AN - SCOPUS:84863518029

VL - 32

SP - 1113

EP - 1119

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 7

ER -